

The invention relates to IL-18 mutant polypeptides including mutations in one or several amino-acid residues participating in its interaction with IL-18- binding protein where mutations in the residue selected from Glu-42 and Lys-89 of IL-18 prehomoid coded by cDNA with sequence SEQ ID NO:1 and where the mutations are present as a nonconservative substitutions; an extracted DNA; the vector including DNA and the pharmaceutical composition.